Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Acute myelogenous leukemia (AML) is a deadly disease characterized by high relapse rates, despite the ability of patients to initially enter complete remission. 1 Although new therapeutics are urgently needed, standard chemotherapy for AML has remained largely unchanged during the past four decades and the therapeutic outcomes remain dismal. The relapse in AML is thought to be driven by leukemia stem cells (LSCs), a chemoresistant subpopulation capable of initiating and re-establishing disease. 2 Studies correlating LSC proportion within individual patients to relapse-free survival have established that higher proportions of LSCs at diagnosis are associated with inferior relapse-free survival. 3 Thus, as LSCs resist
Accepted article preview online 16 December 2015; advance online publication, 12 January 2016 standard therapy, devising new therapeutic strategies that ablate LSCs are likely to improve outcomes. We have shown previously that LSC survival is extensively dependent on constitutively active NF-κB. 4 Indeed, preclinical agents such as parthenolide (PTL) that potently suppress NF-κB can eliminate LSCs in vitro while preserving normal hematopoietic stem cell function. 5 Despite its in vitro efficacy, PTL exhibits poor solubility, high reactivity with serum and poor pharmacokinetics 6 that make it insufficiently bioavailable, limiting its in vivo use. Furthermore, LSCs preferentially reside in the bone marrow (BM) niche, a microenvironment that simultaneously supports LSC survival and provides chemoprotection. 7 To overcome this protective effect, in this study, we evaluated whether encapsulation of PTL into nanoparticles and using a BM-directed multistage vector (MSV) system (MSV-PTL) would deliver active PTL at sufficiently levels to ablate LSCs in vivo.
Our previous studies have sought to optimize PTL using medicinal chemistry, producing the more bioavailable and soluble derivative dimethylaminoparthenolide (DMAPT), which required a 3 × a day oral dosing in a daily schedule to be used in animals ( Figure 1a , top panel). 8 As an alternative approach to optimize PTL delivery we developed a MSV system (MSV-PTL) in which PTL is first incorporated into methoxypoly(ethylene glycol)-poly(lactic acid) (mPEG-PLA) micelles, encapsulated in a protective degradable porous silicon (pSi) particles and coated with E-selectin thioaptamer (ESTA) to direct the particles to the BM 9 (Supplementary Figure 1a) . The pSi-ESTA conjugate binds to E-selectin with nanomolar affinity (K D = 47 nM) and with minimal cross-reactivity to other selectin family members, enabling delivery of PTL to the BM 10, 11 as E-selectin is expressed on the BM endothelium. Primary AML cells were obtained with informed consent and Institutional Review Board approval from Weill Cornell Medical College-New York Presbyterian Hospital. Primary cryopreserved AML samples were thawed and prepared for xenotransplants as described previously. 13 Nonobese diabetic/severe combined iImmunodeficiency mice were then injected via tail vein (5-10 animals per cohort). Treatment with MSV or MSV-PTL (one billion particles) was started 5 weeks after transplantation and mice were treated once every 2 weeks for 4 weeks. The presence of human cells was evaluated by flow cytometry. For the secondary transplants, equal numbers of human cells were injected (5 animals per cohort). The percentage of human AML cells was determined by staining the cells with antibodies for PE-Cy5 rat anti-mouse CD45 (eBiosciences, San Diego, CA, USA) and APC-H7 anti-human CD45 (BD Biosciences, San Jose, CA, USA). For viability, Annexin V-FITC (BD Biosciences) and 7-aminoactinomycin (Thermo Fisher Scientific, Waltham, MA, USA) were used. For intracellular assays, cells were fixed with 4% formaldehyde and permeabilized with methanol. Analyses and graphs were performed using GraphPad Software, Inc. (La Jolla, CA, USA) to evaluate the significance. The specific test utilized is indicated in the figure legends *P o0.05, **P o0.01. (Additional methods can be found in the Supplementary Information).
To evaluate the therapeutic efficacy of MSV-PTL, we established patient-derived AML xenografts (AML-PDXs). The AML-PDXs were treated with either: (i) PBS; (ii) empty-MSV; (iii) PTL-loaded micelles (micelle-PTL); and (iv) MSV-PTL. Empty-MSV and MSV-PTL particles (one billion per mouse) were administered intravenously once every (Figure 1a, bottom panel) for a total of two doses per animal. We found that treatment with two doses containing 50 μg of PTL delivered via MSV-PTL (~2.5 mg/kg) resulted in a significant decrease in AML tumor burden (20% decrease AML9-PDX to 60% decrease AML4-PDX) when compared with PBS, MSV-empty or micelle-PTL-treated mice (no significant change among these groups in both AML-PDX tested; Figure 1b) . Therefore, the MSV system was highly effective for enhancing small molecule delivery. Importantly, we found that mice receiving two treatments MSV-PTL containing 50 μg of PTL nanoparticles spaced 2 weeks apart, resulted in effective killing of leukemia cells in vivo, using~40-fold lower dosage and 20-fold lower frequency that the chemical analog of PTL (DMAPT; used at minimal activity doses). 8 We corroborated that the system can effectively deliver PTL to the mouse BM, using MSV loaded with non-specific-siRNA labeled with Alexa555. AML-PDX animals were treated with the MSV particles with one bolus dose as shown in the schema (Figure 1c) . We found MSV-delivery to human cells by the detection of Ax555-positive human AML cells obtained from the mouse BM 16 h after injection with MSV-siRNA-Ax555 compared with empty particles or MSV-PTL controls (Supplementary Figure 1b) . Furthermore, we observed the inhibition of NF-κB and activation of γ-H2AX in the human cells obtained from the mouse BM, which are known activities of PTL (Supplementary Figure 1c) 5,14 as soon as 16 h of treatment with MSV-PTL, further demonstrating that the MSV system delivered active PTL to the murine BM. Together, these data suggest that the MSV system can effectively release drugs to mouse BM, thus enabling an otherwise low-bioavailability drug to kill AML cells.
weeks for 4 weeks
Importantly, we evaluated the concentration of PTL in plasma and bones from the AML-PDX mice 1 h after administration of nanoparticles (Figure 1c) . Strikingly, PTL was not detected in the plasma at the 1-h time point, thus indicating that there was likely no degradation of the MSV-PTL nanoparticles to release PTL in plasma. PTL was only detected in bone samples (Figure 1d) . The average concentration of PTL was 375.0 ± 14.7 nM (n = 4). Our data demonstrate that PTL was delivered in chemically intact form to the bone tissue and not released into the plasma.
Because PTL is known to be an anti-LSC agent, we evaluated the impact of the in vivo treatment on LSC function by performing secondary xenotransplants, injecting equal numbers of human AML cells from the treated mice (Figure 2a) . Treatment with MSV-PTL resulted in a 3.7-fold and 2.2-fold reduction in secondary AML engraftment, compared with the MSV control group (P o0.05) for cells obtained from AML9-PDX and AML4-PDX, respectively (Figure 2b) . The reduced level of secondary engraftment demonstrated that directed delivery of PTL to the BM using the MSV system resulted in killing of LSCs.
To corroborate the biological activity of PTL, we next analyzed the intracellular changes characteristic of PTL that are indicative of drug target engagement. Human cells from AML-PDX mice were evaluated after the in vivo treatment regimen with MSV-PTL. Two known features that reflect the anti-leukemia activity of PTL are inhibition of NF-κB and activation of γH2AX.
14 Using immunoblots, confocal microscopy and flow cytometry, we demonstrated that treatment with MSV-PTL indeed resulted in increased inhibition of NF-κB and elevated activation of γ-H2AX. In contrast, PBS, MSV-empty and micelle-PTL did not demonstrate these activities (Figures 2c-f) .
Translation of in vitro preclinical findings to the clinic represents a significant obstacle in improving patient outcomes in AML where novel therapies are urgently needed. Often, a major hurdle is development chemical derivatives with useful drug-like characteristics, which can significantly delay the development of new therapeutics and clinical trials. One such example is the small molecule natural product PTL, which has established potent anti-LSC activity in AML in vitro.
This study demonstrates the efficacy and utility of encapsulating unmodified preclinical small molecules such as PTL in a MSV system to facilitate delivery to the tumor niche. LSCs reside within and are protected by the BM niche. 7 Encapsulation of PTL into the MSV coated with ESTA resulted in rapid delivery of chemically intact PTL to the BM niche. Two doses of MSV-PTL delivered 2 weeks apart were capable of reducing AML burden and markedly impairing LSC function in vivo. The poor bioavailability and pharmacokinetic profile of PTL were overcome by encapsulation in the MSV, producing in vivo efficacy against LSCs using AML-PDX mice. Indeed, PTL delivered via this system engaged cellular responses consistent with PTL activity, leading to a decrease in both AML burden and LSC function. Overall, these studies demonstrate that the use of targeted MSV nanoparticles is a novel and promising therapeutic approach in AML by facilitating anti-LSC small molecules such as PTL to the BM niche. 4 distinguish the two types of t (11;19); instead they combine both into one cytogenetic group. Herein, we report the largest, to our knowledge, series of 35 adults with acute leukemia and t(11;19)(q23;p13.1) or t(11;19)(q23;p13.3) who were treated on Cancer and Leukemia Group B (CALGB)/ Alliance for Clinical Trials in Oncology (Alliance) trials. Our study is also the largest to describe the clinical features and disease outcomes of these patients as well as to provide mutational analyses, and gene-and microRNA (miR)-expression patterns, thereby providing the rationale to identify each as separate entities.
Leukemia
We identified and clinically characterized 19 adults with t(11;19) (q23;p13.1) and AML and 16 with t(11;19)(q23;p13.3), 12 with AML, three with ALL and one with ambiguous lineage acute leukemia (ALAL), who received AML-directed therapy and is grouped with AML patients, enrolled onto a prospective cytogenetics companion trial, CALGB 8461. We also performed RNA, microRNA and targeted DNA-sequencing studies on subsets of patients in each cytogenetic group. See Supplementary Information for methods details.
Translocation (11;19)(q23;p13.1) was found exclusively in AML patients; however, t(11;19)(q23;p13.3) was detected in both AML and ALL patients. The only significant clinical differences between AML patients with either translocation were the higher marrow (P = 0.003) and blood (P = 0.004) blast percentages in patients with t(11;19)(q23;p13.3) ( Table 1) . Among AML patients, there were no major differences between the two cytogenetic groups with respect to complete remission (CR) rates, disease-free survival or overall survival. Both translocations were associated with a poor prognosis, with a median overall survival of 8.2 months for t(11;19) (q23;p13.1) patients and 10.0 months for t(11;19)(q23;p13.3) AML patients ( Table 1 , Supplementary Figure S1 ). The median follow-up for the four patients alive and without an event is 6.9 years.
Four (21%) t(11;19)(q23;p13.1) patients underwent either autologous (patients no. 3, 16) or allogeneic (no. 5, 6) hematopoietic stem-cell transplantation (HSCT) in CR1. Two (15%) AML patients with t(11;19)(q23;p13.3) received autologous (no. 30) or allogeneic (no. 25) HSCT in CR1. Three of these six patients remain alive and disease-free at last follow-ups of 38.4 months (no. 6), 90.7 months (no. 25) and 134.3 months (no. 30) after diagnosis. Clinical and cytogenetic data for individual patients are provided in Supplementary Tables S1-S3 .
We compared our findings with the literature and found them mostly concordant (Supplementary Tables S4 and S5 ). Others have also found t(11;19)(q23;p13.1) exclusively in AML patients, who were primarily female and had M4/M5 marrow morphology. However, t(11;19)(q23;p13.3) patients in the literature were mainly male, whereas two-thirds of CALGB/Alliance patients with t(11;19) (q23;p13.3) were female.
Cytogenetically, t(11;19)(q23;p13.3) AML patients tended to have a higher incidence of secondary chromosome abnormalities at diagnosis than AML patients with t(11;19)(q23;p13.1) (62% vs 26%, P = 0.07). In most t(11;19)(q23;p13.1) patients (74%), the translocation was detected as an isolated chromosome abnormality; however, five patients had additional clonal abnormalities including trisomy 8 (+8), trisomy 21, paracentric inversion within 12p, deletion of 20q and a complex karyotype. The most common secondary abnormality was +8, found in six AML patients, but its incidence was higher among patients with t(11;19)(q23;p13.3) than those with t(11;19)(q23;p13.1) (83% vs 17%) (Supplementary  Tables S1 and S2 ). In six of the seven patients for whom cytogenetic data were available at the time of relapse, the translocation present at diagnosis was also found at relapse.
When we combined our data with the literature, secondary abnormalities occurred significantly more often in t(11;19) (q23;p13.3) patients (55% vs 21%, P o 0.001). Our data and the Accepted article preview online 16 December 2015; advance online publication, 19 January 2016
